Applying a "Fast-to-Phase II" model, KineMed is working with leading pharmaceutical companies to select highly qualified drug candidates and rapidly demonstrate their therapeutic activity in patients. KineMed's most advanced programs are detailed below.

Atherosclerosis
Atherosclerosis or "hardening of the arteries" is the leading cause of death in the United States. Reverse cholesterol transport, the removal of cholesterol from arterial plaques, is one of the most sought after therapeutic targets today. KineMed's technology measures reverse cholesterol transport, a critical mechanism to reduce cholesterol levels and plaque size. More.

Diabetes & Pre-Diabetes
Diabetes is the 6th leading cause of death in the United States. In recent years, the incidence of diabetes and obesity has grown dramatically. Insulin resistance is considered to be a major risk factor for the development of type 2 Diabetes, and is the target of several anti-diabetic drugs. KineMed is identifying and developing drugs for insulin resistance through the use of its unique and minimally invasive method. This method directly measures insulin resistance and pancreatic function in humans and animals. More.

Neurological Diseases
Diseases involving neurodegeneration and neurogenesis are a growing concern as the Baby Boom generation enters the years of greatest risk. KineMed has applied its proprietary technology to effectively identify drugs that stimulate neurogenesis for the treatment of cognitive and mood disorders. At the same time, KineMed is applying its insights into a unique mechanism of neurodegeneration to identify novel therapeutic approaches to amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. More.

Osteoarthritis, fibrosis, and inflammation
Osteoarthritis is by far the most common type of arthritis. By 2030, 20% of Americans — about 72 million people — will be over 65 years of age and at high risk for the disease. KineMed technology measures extracellular matrix (collagen or glucosaminoglycan) synthesis in the joint space, lung, kidney, and liver, an excellent marker for this disease pathway. More.

Other Disease Areas
The KineMed technology is extremely versatile and amenable to many disease programs. As an example, nine patents have been issued, and more than 100 patent applications have been filed. More.